Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups

Cancer Biology and Therapy

Volumn 16, Issue 1, 2015, Pages 60-65

  Gomez Bougie, Patricia ^a,b   Halliez, Maxime ^a,b   Maïga, Sophie ^a,b   Godon, Catherine ^b   Kervoëlen, Charlotte ^a   Pellat Deceunynck, Catherine ^a,b   Moreau, Philippe ^b   Amiot, Martine ^a,b  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

apoptosis; Bcl 2 molecules; curcumin; Mcl 1; Myeloma

Indexed keywords

CASPASE 3; CURCUMIN; PROTEIN MCL 1; PROTEIN P53; ANTINEOPLASTIC AGENT;

ANTIAPOPTOTIC ACTIVITY; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL DEATH; DOWN REGULATION; DRUG EFFECT; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LD50; MULTIPLE MYELOMA; MYELOMA CELL LINE; PLASMA CELL; SURVIVAL FACTOR; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CASPASE 3; CELL DEATH; CELL LINE, TUMOR; CURCUMIN; DRUG RESISTANCE, NEOPLASM; HUMANS; MULTIPLE MYELOMA; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PLASMA CELLS; PROGNOSIS;

EID: 84946712513     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/15384047.2014.986997     Document Type: Article

References (23)

1. Milacic V, Banerjee S, Landis-Piwowar KR, Sarkar FH, Majumdar AP, Dou QP. Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res 2008; 18:7283-92; PMID:18794115; http://dx.doi.org/10.1158/0008-5472.CAN-07-6246
2. Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 2005; 5:700-13; PMID:16023083; http://dx.doi.org/10.1016/j.bcp.2005.04.043
3. + cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis. Blood 2004; 103:3175-84; PMID:15070700; http://dx.doi.org/10.1182/blood-2003-06-2151
4. Bharti AC, Donato N, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human myeloma cells. J Immunol 2003; 171:3863-71; PMID:14500688; http://dx.doi.org/10.4049/jimmunol.171.7.3863
5. Park J, Ayyappan V, Bae EK, Lee C, Kim BS, Kim BK, Lee YY, Ahn KS, Yoon SS. Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. Mol Oncol 2008; 2:317-26; PMID:19383353; http://dx.doi.org/10.1016/j.molonc.2008.09.006
6. Sung B, Kunnumakkara GS, Sethi G, Anand P, Gluha S, Aggarwal BB. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and botezomib against human multiple myeloma in nude mice model. Mol Cancer Ther 2009; 8:959-70; PMID:19372569; http://dx.doi.org/10.1158/1535-7163.MCT-08-0905
7. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, et al. The molecular classification of multiple myeloma. Blood 2006; 108:2020-28; PMID:16728703; http://dx.doi.org/10.1182/blood-2005-11-013458
8. Chesi M, Bergsagel PL. Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol 2013; 97:313-23; PMID:23456262; http://dx.doi.org/10.1007/s12185-013-1291-2
9. Johnson SK, Heuck CJ, Albino AP, Qu P, Zhang Q, Shaughnessy JDJr. The use of molecular-base risk stratification and pharmacogenomics for outcome prediction and personalized therapeutic management of multiple myeloma. Int J Hematol 2011; 94:321-33; PMID:22002477; http://dx.doi.org/10.1007/s12185-011-0948-y
10. -1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Leukemia 2005; 9:1248-52; PMID:15902294; http://dx.doi.org/10.1038/sj.leu.2403784
11. -2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs 2011; 1:59-70; PMID:20812891; http://dx.doi.org/10.1517/14728214.2010.515210
12. Surget S, Chiron D, Gomez-Bougie P, Descamps G, Ménoret E, Bataille R, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C. Cell Death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer Res 2012; 17:4562-73; PMID:22738917; http://dx.doi.org/10.1158/0008-5472.CAN-12-0487
13. Jourdan M, Ferlin M, Legouffe E, Horvathova M, Liautard J, Rossi JF, Wijdenes J, Brochier J, Klein B. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol 1998; 100:637-46; PMID:9531328; http://dx.doi.org/10.1046/j.1365-2141.1998.00623.x
14. -x(L) is an essential survival protein of human myeloma cells. Blood 2002; 100:194-99; PMID:12070027; http://dx.doi.org/10.1182/blood.V100.1.194
15. Bodet L, Gomez-Bougie P, Touzeau C, Dousset C, Descamps G, Maïga S, Avet-Loiseau H, Bataille R, Moreau P, Le Gouill S, et al. ABT-737 is highly effective against molecular subgroups of multiple myeloma. Blood 2011; 118: 3901-10; PMID:21835956; http://dx.doi.org/10.1182/blood-2010-11-317438
16. Gomez-Bougie P, Amiot M. Apoptotic machinery diversity in multiple myeloma molecular subtypes. Front Immunol 2013; 4:1-6; PMID:23355837; http://dx.doi.org/10.3389/fimmu.2013.00467
17. Surget S, Lemieux-Blanchard E, Maïga S, Descamps G, Le Gouill S, Moreau P, Amiot M, Pellat-Deceunynck C. Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other. Leuk Lymphoma 2014; Epub ahead of print; PMID:24308434
18. Moreau P, Avet-Loiseau H, Harousseau JL, Attal M. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol 2011; 9:1898-06; PMID:21482979; http://dx.doi.org/10.1200/JCO.2010.32.5878
19. Lodé L, Eveillard M, Trichet V, Soussi T, Wuillème S, Richebourg S, Magrangeas F, Ifrah N, Campion L, Traullé C et al. Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma. Haematologica 2010; 95:1973-76; PMID:Can't; http://dx.doi.org/10.3324/haematol.2010.023697
20. Bush JA, Cheung KJJr, Li G. Curcumin induces apoptosis in human melanoma cells through a Fas/receptor/caspase-8 pathway independent of p53. Exp Cell Res 2001; 2:305-14; PMID:11716543; http://dx.doi.org/10.1006/excr.2001.5381
21. Golombick T, Diamond TH, Manoharan A, Ramakrishna R. Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: A randomized, double-blind placebo controlled cross-over 4g study and an open-label 8g extension study. Am J Hematol 2012; 5:455-60; PMID:11716543; http://dx.doi.org/10.1002/ajh.23159
22. Moreaux J, Klein B, Bataille R, Descamps G, Maïga S, Hose D, Goldschmidt H, Jauch A, Rème T, Jourdan M et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 2011; 4:574-82; PMID:21173094; http://dx.doi.org/10.3324/haematol.2010.033456
23. -1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 2007; 67:5418-24; PMID:17545623; http://dx.doi.org/10.1158/0008-5472.CAN-06-4322